Method and Compositions for the Diagnosis of a Thyroid Condition
OwnerPaul G. WALFISH, Ranju RALHANinventors
Life of this patent
Estimating the term…
Abstract
Methods for detecting thyroid cancer or for differentiating malignant thyroid tissue from non-malignant thyroid tissue comprises measuring the amount of one or more of PGK1, PKM2, PTEN, Profilin-1, S100A6, Galectin-3 and Cyclin D1 and measuring under-expression or over-expression of these markers in comparison to normal tissue. The methods can be used with a fine needle aspiration biopsy (FNAB), a core biopsy or a cytosmear.
Claims18
A method for diagnosing thyroid cancer, or for differentiating malignant or pre-malignant thyroid tissue from non-malignant thyroid tissue in a subject, the method comprising:
- comparing a detected amount of nuclear or cytoplasmic PGK1 in a thyroid tissue sample from the subject with a control amount of PGK1 in non-cancerous tissue;
- and diagnosing thyroid cancer or identifying malignant thyroid tissue in the subject when the detected amount of PGK1 is less than the control amount.
A method for diagnosing thyroid cancer, or for differentiating malignant or pre-malignant thyroid tissue from non-malignant thyroid tissue in a subject, the method comprising:
- comparing detected amounts of PGK1 and Galectin-3 in a thyroid tissue sample from the subject with control amounts of PGK1 and Galectin-3 in non-cancerous tissue;
- and diagnosing thyroid cancer or identifying malignant thyroid tissue in the subject when the detected amount of PGK1 is less than the control amount of PGK1 and the detected amount of Galectin-3 is greater than the control amount of Galectin-3.
A method for diagnosing thyroid cancer, or for differentiating malignant or pre-malignant thyroid tissue from non-malignant thyroid tissue in a subject, the method comprising:
- comparing detected amounts of two or more biomarkers in a thyroid tissue sample from the subject with control amounts of the biomarkers in non-cancerous tissue, the biomarkers comprising PGK1, PKM2, PTEN, Profilin-1, Galectin-3 and Cyclin D1;
- and diagnosing thyroid cancer or identifying malignant thyroid tissue in the subject when (i) the detected amounts of PGK1, PKM2, PTEN, Profilin-1 or S100A6 are less than the respective control amounts and/or (ii) the detected amounts of Cyclin D1 or Galectin-3 are greater than the respective control amounts.
A method for diagnosing thyroid cancer, or for differentiating malignant or pre-malignant thyroid tissue from non-malignant thyroid tissue in a subject, the method comprising:
- comparing an amount of Profilin-1 detected in a thyroid tissue sample from the subject with a control amount of Profilin-1 in non-cancerous tissue;
- and diagnosing thyroid cancer or identifying malignant thyroid tissue in the subject when the detected amount of Profilin-1 is less than the control amount.
Dependencies are inferred from the claim text.